In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

The double ring, spool-like structure of RAD52 protects replicating DNA in dividing cells. A study led by the University of ...

A new study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP ...

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

Sky News presenter Jacquie Beltrao has lived in her stylish home in south-west London for 12 years with her husband Eduardo ...

Data shows Norway, which is similar in population size to NZ, increased its five-year survival rates for ovarian cancer from 34.1% to 46.1% in the almost two decades from 1995. In contrast, New ...

Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease progression when added to the standard-of-care, Genentech’s ...

Dr Emma Bolderson, from QUT's School of Biomedical Sciences, has received a $460,552 grant from the Ovarian Cancer Research ...

A new study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP ...